Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q2 2023 · 10-Q
Revenue$32.20M$32.20M+12.4% vs Q2 2022 Net Income-$85.63M-$85.63MN/M vs Q2 2022 EPS Diluted-$1.13-$1.13N/M vs Q2 2022 Operating Income-$103,951,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$69,300,000N/M Margins · derivedOperating margin-322.9%−48.6 pt vs Q2 2022
Net margin-266.0%−31.9 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 3, 2023 · 34 d after period end